Antiviral screening shows cytopathic effect in Rhabdomyosarcoma cells, suggesting potential drug candidates may reduce virus effects.
The following is a protocol for live virus antiviral screening against EV-D68 in vitro on Rhabdomyosarcoma (RD) cells. RD Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity. IC50 values are generated via analysis of MTT/MTS data as a readout of CPE (cytopathic effect). Each live virus screening assay is accompanied by a matching cytotoxicity screening assay in uninfected cells to investigate drug toxicity.
No takes yet. Share an insight, caveat, or question.
Nick Lynch (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: